OHE Publications

OHE releases a number of publications throughout the year, authored by OHE team members and/or outside experts. All are free for download as pdf files; hard copies of some publications are available upon request.

A description of the OHE publications categories.


 

Sussex, J., Shah, K. and Butler, J.

Consulting Report
October 2010

This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in Australia. It includes observations as to whether and how the economic assessment process differs for vaccines compared to curative pharmaceutical products and implications of central purchasing for economic efficiency.

Sussex, J. and Shah, K.

Consulting Report
October 2010

This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in the UK. It includes observations as to whether and how the economic assessment process differs for vaccines compared to curative pharmaceutical products and the implications of the current pricing approach.

Sharma, P. and Towse, A.

Occasional Paper
October 2010

Antimicrobial resistance (AMR) to drugs, a natural and unavoidable consequence of treating infectious diseases, is a growing global public health threat. The EU Commission is to develop comprehensive proposals by the end of 2012 for addressing the situation. This Paper is meant to provide input into those policy discussions.

The paper reviews AMR’s implications for the burden of disease, the causes of AMR, the current state of the antibiotic development pipeline and the reasons antibiotic R&D has been de-emphasised by biopharmaceutical companies.

Office of Health Economics and RAND Europe

Occasional Paper
October 2010

Research spillovers may exist when research by one organisation creates increased output for other organisations that operate in the same or another sector of the economy.  Both the mechanisms and the ultimate value of this transfer of ideas, knowledge or know-how still are not fully understood and virtually all such research on spillovers has been focused outside the UK.  Given current constraints on public, charitable and private research funding, enhancing spillovers may become an important objective in UK science and technology policy.

Garber, A.M.

Monograph
September 2010

The speaker for the OHE’s 17th Annual Lecture was Dr Alan Garber, Director both of Stanford University’s Center for Health Policy and its Center for Primary Care and Outcomes Research at the School of Medicine. His remarks focused on the national health care legislation enacted in March 2010 in the US from a unique perspective – as a practicing professor of medicine, one of the world’s leading health economists, and an expert in health care policy.  His overview touched on several of the key issues raised by the new law that relate to coverage, cost, and quality.

Garau, M. and Mestre-Ferrandiz, J.

Briefing
November 2009

This study compares pricing and reimbursement (P&R) policy for 43 orphan medicinal products (OMPs) across seven EU Member States: France, Germany, Italy, The Netherlands, Spain, Sweden and the UK. Examined in particular are the standards of evidence and the criteria for P&R decisions, the availability of access before full licensing approval, and requirements for studies after the drug is available on the market.

Sussex, J.

Briefing
September 2009

Written while Labour Government policies still were in force, this Briefing clearly and thoroughly examines non-discretionary cost differences between public and independent providers that may have a serious impact on the effectiveness of competition.  Four key differences are identified: corporation tax, value added tax, pension costs and cost of capital.  Critical barriers to implementing the competition policy are reviewed.

Pages